Latigo Bio key facts
as of Oct 2026- Operator of a biotechnology company intended to develop novel and non-opioid therapies for chronic pain.
- Latigo Bio is valued at approximately $530.0M as of Oct 2026 (last reported valuation).
- It has raised $304.0M; the latest was Later Stage VC ($150.0M) in Mar 2025.
- Notable investors include Alexandria Venture Investments, Qatar Investment Authority, Blue Owl Capital, Foresite Capital, Cormorant Asset Management — 14 tracked in total.
- Status: Privately Held (backing).
Latigo Bio's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Latigo Bio: the Monday email on marks, rounds and moves
Latigo Bio funding rounds
No funding rounds for Latigo Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Latigo Bio
14+Latigo Bio valuation
Latigo Bio's last reported valuation was $530 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Latigo Bio investors
14 investors are on record for Latigo Bio, including Alexandria Venture Investments, Qatar Investment Authority, Blue Owl Capital and Foresite Capital. By type, the record holds 4 venture capital firms, 1 hedge fund and 1 asset manager.
About Latigo Bio
Operator of a biotechnology company intended to develop novel and non-opioid therapies for chronic pain. The company's platform offers translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependence, or tolerability.
- Sector
- Healthcare
- HQ
- Thousand Oaks, CA, United States
- Founded
- 2018
- Employees
- 44
- Website
- latigobio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.